500 Per Cent Multibagger Returns: Board of This Specialty Chemicals & Pharma Company Announces 10:1 Stock Split; Check Record Date Inside

500 Per Cent Multibagger Returns: Board of This Specialty Chemicals & Pharma Company Announces 10:1 Stock Split; Check Record Date Inside

The stock gave multibagger returns of over 500 per cent from its 52-week low of Rs 58.20 per share.

Today, shares of Sudarshan Pharma Industries Ltd plunged 2.07 per cent to Rs 402.50 per share from its previous closing of Rs 411 per share with an intraday high of Rs 403 and an intraday low of Rs 393. The stock’s 52-week high is Rs 452.70 per share while its 52-week low is Rs 58.20 per share.

The Board of Directors of the company approved a sub-division /stock split of the company’s 1 (one) equity share having a face value of R 10 each fully paid-up, into 10 equity shares of the company having a face value of Re 1 each fully paid-up. The reason behind the split is to enhance the liquidity of the company’s share and to make it more affordable for small investors and also to broaden the company's investor base. The Board fixed the record date for stock split as Monday, November 18, 2024.

Sudarshan Pharma Industries Limited (SPIL), established in 2008 and headquartered in Mumbai, is a prominent contract manufacturer of generic formulations. Operating across diverse segments, including specialty chemicals, intermediates, APIs, pharmaceutical and formulation generics, and bulk supply, SPIL caters to a wide range of institutions and healthcare organizations. Beyond its contract manufacturing services, SPIL has ventured into branded products through its Vimac Healthcare division. A significant portion of its product portfolio, consisting of 56 out of 96 items, is registered under the "R" trademark. Furthermore, SPIL collaborates with renowned Indian companies and institutional clients, offering contract manufacturing services for pharmaceutical formulations and medicines.

DSIJ’s ‘Micro Marvel' service recommends micro-cap stocks with the potential to grow multifold in long run. If this interests you, do download the service details here.

Earlier, the company acquired 2,09,100 equity shares of Ishwari Healthcare Private Limited (Ishwari Healthcare), representing 51 per cent of its paid-up equity share capital, was completed. Upon completion of the acquisition, Ishwari Healthcare became a subsidiary of the Company. Ishwari Healthcare was a private limited company engaged in the business of producing, processing, preparing, treating, disinfecting, compounding, formulating, mixing, concentrating, packing, repacking, refining, adding, removing, purifying, preserving, grading, freezing, distillation, boiling, sterilizing, improving, extracting, buying, selling, reselling, trading, importing, exporting, bartering, transporting, storing, forwarding, distributing, disposing, developing, researching, discovering, manipulating, marketing, supplying, and dealing in various medical and surgical instruments, equipment, goods, products, instruments, apparatus, and devices related to all branches of medicine, surgery, and healthcare.

The company has a market cap of Rs 969 crore and has delivered good profit growth of 37 per cent CAGR over the last 5 years. The stock gave multibagger returns of over 500 per cent from its 52-week low of Rs 58.20 per share. Investors should keep an eye on this micro-cap stock.

Disclaimer: The article is for informational purposes only and not investment advice. 

Rate this article:
3.6

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary21-Nov, 2024

Multibaggers21-Nov, 2024

Mindshare21-Nov, 2024

Mindshare21-Nov, 2024

Mindshare21-Nov, 2024

Knowledge

MF15-Nov, 2024

General15-Nov, 2024

MF14-Nov, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR